-
2
-
-
84883013481
-
Management of non-small-cell lung cancer: Recent developments
-
Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: Recent developments. Lancet 382: 709-719, 2013.
-
(2013)
Lancet
, vol.382
, pp. 709-719
-
-
Reck, M.1
Heigener, D.F.2
Mok, T.3
Soria, J.C.4
Rabe, K.F.5
-
3
-
-
84937563758
-
PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
-
Ji M, Liu Y, Li Q, Li XD, Zhao WQ, Zhang H, Zhang X, Jiang JT and Wu CP: PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med 13: 5, 2015.
-
(2015)
J Transl Med
, vol.13
, pp. 5
-
-
Ji, M.1
Liu, Y.2
Li, Q.3
Li, X.D.4
Zhao, W.Q.5
Zhang, H.6
Zhang, X.7
Jiang, J.T.8
Wu, C.P.9
-
4
-
-
84924577386
-
Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumorinfiltrating T cells and the status of oncogenic drivers
-
Kim MY, Koh J, Kim S, Go H, Jeon YK and Chung DH: Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumorinfiltrating T cells and the status of oncogenic drivers. Lung Cancer 88: 24-33, 2015.
-
(2015)
Lung Cancer
, vol.88
, pp. 24-33
-
-
Kim, M.Y.1
Koh, J.2
Kim, S.3
Go, H.4
Jeon, Y.K.5
Chung, D.H.6
-
5
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
-
Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
-
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246, 2012.
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
Vergnenegre, A.4
Massuti, B.5
Felip, E.6
Palmero, R.7
Garcia-Gomez, R.8
Pallares, C.9
Sanchez, J.M.10
-
6
-
-
84898748420
-
Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: A meta-analysis
-
Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH and Heo DS: Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: A meta-analysis. JAMA 311: 1430-1437, 2014.
-
(2014)
JAMA
, vol.311
, pp. 1430-1437
-
-
Lee, J.K.1
Hahn, S.2
Kim, D.W.3
Suh, K.J.4
Keam, B.5
Kim, T.M.6
Lee, S.H.7
Heo, D.S.8
-
7
-
-
84904898065
-
AZD9291, an irreversible EGFR TKI, overcomes T790Mmediated resistance to EGFR inhibitors in lung cancer
-
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, et al: AZD9291, an irreversible EGFR TKI, overcomes T790Mmediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4: 1046-1061, 2014.
-
(2014)
Cancer Discov
, vol.4
, pp. 1046-1061
-
-
Cross, D.A.1
Ashton, S.E.2
Ghiorghiu, S.3
Eberlein, C.4
Nebhan, C.A.5
Spitzler, P.J.6
Orme, J.P.7
Finlay, M.R.8
Ward, R.A.9
Mellor, M.J.10
-
8
-
-
84890020587
-
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
-
Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, et al: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3: 1355-1363, 2013.
-
(2013)
Cancer Discov
, vol.3
, pp. 1355-1363
-
-
Akbay, E.A.1
Koyama, S.2
Carretero, J.3
Altabef, A.4
Tchaicha, J.H.5
Christensen, C.L.6
Mikse, O.R.7
Cherniack, A.D.8
Beauchamp, E.M.9
Pugh, T.J.10
-
9
-
-
84923072443
-
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
-
Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, et al: Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 25: 1935-1940, 2014.
-
(2014)
Ann Oncol
, vol.25
, pp. 1935-1940
-
-
Azuma, K.1
Ota, K.2
Kawahara, A.3
Hattori, S.4
Iwama, E.5
Harada, T.6
Matsumoto, K.7
Takayama, K.8
Takamori, S.9
Kage, M.10
-
10
-
-
84931054440
-
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
-
Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, Chen N, Zhan J, He X, Qin T, et al: The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 6: 14209-14219, 2015.
-
(2015)
Oncotarget
, vol.6
, pp. 14209-14219
-
-
Tang, Y.1
Fang, W.2
Zhang, Y.3
Hong, S.4
Kang, S.5
Yan, Y.6
Chen, N.7
Zhan, J.8
He, X.9
Qin, T.10
-
11
-
-
84920655625
-
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
-
D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, et al: PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 112: 95-102, 2015.
-
(2015)
Br J Cancer
, vol.112
, pp. 95-102
-
-
D'Incecco, A.1
Andreozzi, M.2
Ludovini, V.3
Rossi, E.4
Capodanno, A.5
Landi, L.6
Tibaldi, C.7
Minuti, G.8
Salvini, J.9
Coppi, E.10
-
12
-
-
84896713991
-
The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone
-
Afreen S and Dermime S: The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. Hematol Oncol Stem Cell Ther 7: 1-17, 2014.
-
(2014)
Hematol Oncol Stem Cell Ther
, vol.7
, pp. 1-17
-
-
Afreen, S.1
Dermime, S.2
-
13
-
-
84921308811
-
The PD-1/PD-L1 pathway: Biological background and clinical relevance of an emerging treatment target in immunotherapy
-
Muenst S, Soysal SD, Tzankov A and Hoeller S: The PD-1/PD-L1 pathway: Biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert Opin Ther Targets 19: 201-211, 2015.
-
(2015)
Expert Opin Ther Targets
, vol.19
, pp. 201-211
-
-
Muenst, S.1
Soysal, S.D.2
Tzankov, A.3
Hoeller, S.4
-
14
-
-
84928774156
-
The future of immune checkpoint therapy
-
Sharma P and Allison JP: The future of immune checkpoint therapy. Science 348: 56-61, 2015.
-
(2015)
Science
, vol.348
, pp. 56-61
-
-
Sharma, P.1
Allison, J.P.2
-
15
-
-
78851471039
-
PD-L1 expression on tolerogenic APCs is controlled by STAT-3
-
Wölfle SJ, Strebovsky J, Bartz H, Sähr A, Arnold C, Kaiser C, Dalpke AH and Heeg K: PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 41: 413-424, 2011.
-
(2011)
Eur J Immunol
, vol.41
, pp. 413-424
-
-
Wölfle, S.J.1
Strebovsky, J.2
Bartz, H.3
Sähr, A.4
Arnold, C.5
Kaiser, C.6
Dalpke, A.H.7
Heeg, K.8
-
16
-
-
33645506849
-
Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor
-
Alvarez JV, Greulich H, Sellers WR, Meyerson M and Frank DA: Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66: 3162-3168, 2006.
-
(2006)
Cancer Res
, vol.66
, pp. 3162-3168
-
-
Alvarez, J.V.1
Greulich, H.2
Sellers, W.R.3
Meyerson, M.4
Frank, D.A.5
-
17
-
-
36849012237
-
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
-
Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, et al: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856, 2007.
-
(2007)
J Clin Invest
, vol.117
, pp. 3846-3856
-
-
Gao, S.P.1
Mark, K.G.2
Leslie, K.3
Pao, W.4
Motoi, N.5
Gerald, W.L.6
Travis, W.D.7
Bornmann, W.8
Veach, D.9
Clarkson, B.10
-
18
-
-
84956573071
-
PDL1 regulation by p53 via miR-34
-
Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al: PDL1 regulation by p53 via miR-34. J Natl Cancer Inst 108: 108, 2015.
-
(2015)
J Natl Cancer Inst
, vol.108
, pp. 108
-
-
Cortez, M.A.1
Ivan, C.2
Valdecanas, D.3
Wang, X.4
Peltier, H.J.5
Ye, Y.6
Araujo, L.7
Carbone, D.P.8
Shilo, K.9
Giri, D.K.10
-
19
-
-
33749316418
-
The epidermal growth factor receptor pathway: A model for targeted therapy
-
Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5268-5272
-
-
Scaltriti, M.1
Baselga, J.2
-
20
-
-
79957492069
-
American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy
-
Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA and Giaccone G: American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29: 2121-2127, 2011.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2121-2127
-
-
Keedy, V.L.1
Temin, S.2
Somerfield, M.R.3
Beasley, M.B.4
Johnson, D.H.5
McShane, L.M.6
Milton, D.T.7
Strawn, J.R.8
Wakelee, H.A.9
Giaccone, G.10
-
21
-
-
31444451661
-
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gammainduced upregulation of B7-H1 (CD274)
-
Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, Oh S, Shin JG, Yao S, Chen L, et al: Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gammainduced upregulation of B7-H1 (CD274). FEBS Lett 580: 755-762, 2006.
-
(2006)
FEBS Lett
, vol.580
, pp. 755-762
-
-
Lee, S.J.1
Jang, B.C.2
Lee, S.W.3
Yang, Y.I.4
Suh, S.I.5
Park, Y.M.6
Oh, S.7
Shin, J.G.8
Yao, S.9
Chen, L.10
-
22
-
-
84891534246
-
Programmed death ligand-1 expression in non-small cell lung cancer
-
Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L and Rimm DL: Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 94: 107-116, 2014.
-
(2014)
Lab Invest
, vol.94
, pp. 107-116
-
-
Velcheti, V.1
Schalper, K.A.2
Carvajal, D.E.3
Anagnostou, V.K.4
Syrigos, K.N.5
Sznol, M.6
Herbst, R.S.7
Gettinger, S.N.8
Chen, L.9
Rimm, D.L.10
-
23
-
-
32544459770
-
Restoring function in exhausted CD8 T cells during chronic viral infection
-
Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ and Ahmed R: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687, 2006.
-
(2006)
Nature
, vol.439
, pp. 682-687
-
-
Barber, D.L.1
Wherry, E.J.2
Masopust, D.3
Zhu, B.4
Allison, J.P.5
Sharpe, A.H.6
Freeman, G.J.7
Ahmed, R.8
-
24
-
-
84928773222
-
IFN- from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
-
Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I and Mandai M: IFN- from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 112: 1501-1509, 2015.
-
(2015)
Br J Cancer
, vol.112
, pp. 1501-1509
-
-
Abiko, K.1
Matsumura, N.2
Hamanishi, J.3
Horikawa, N.4
Murakami, R.5
Yamaguchi, K.6
Yoshioka, Y.7
Baba, T.8
Konishi, I.9
Mandai, M.10
-
25
-
-
84923090821
-
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
-
Ritprajak P and Azuma M: Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol 51: 221-228, 2015.
-
(2015)
Oral Oncol
, vol.51
, pp. 221-228
-
-
Ritprajak, P.1
Azuma, M.2
-
26
-
-
84859128199
-
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
-
Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4: 127ra37, 2012.
-
(2012)
Sci Transl Med
, vol.4
, pp. 127ra37
-
-
Taube, J.M.1
Anders, R.A.2
Young, G.D.3
Xu, H.4
Sharma, R.5
McMiller, T.L.6
Chen, S.7
Klein, A.P.8
Pardoll, D.M.9
Topalian, S.L.10
-
27
-
-
34347400169
-
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
-
Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, Saudemont A and Quesnel B: Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110: 296-304, 2007.
-
(2007)
Blood
, vol.110
, pp. 296-304
-
-
Liu, J.1
Hamrouni, A.2
Wolowiec, D.3
Coiteux, V.4
Kuliczkowski, K.5
Hetuin, D.6
Saudemont, A.7
Quesnel, B.8
-
28
-
-
84903831602
-
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma
-
Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, et al: Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 20: 3446-3457, 2014.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 3446-3457
-
-
Atefi, M.1
Avramis, E.2
Lassen, A.3
Wong, D.J.4
Robert, L.5
Foulad, D.6
Cerniglia, M.7
Titz, B.8
Chodon, T.9
Graeber, T.G.10
-
29
-
-
33846118474
-
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
-
Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et al: Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13: 84-88, 2007.
-
(2007)
Nat Med
, vol.13
, pp. 84-88
-
-
Parsa, A.T.1
Waldron, J.S.2
Panner, A.3
Crane, C.A.4
Parney, I.F.5
Barry, J.J.6
Cachola, K.E.7
Murray, J.C.8
Tihan, T.9
Jensen, M.C.10
-
30
-
-
84900393562
-
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression
-
Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y, Chen Z, Herter-Sprie GS, Akbay EA, Tchaicha JH, Altabef A, et al: Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 25: 590-604, 2014.
-
(2014)
Cancer Cell
, vol.25
, pp. 590-604
-
-
Xu, C.1
Fillmore, C.M.2
Koyama, S.3
Wu, H.4
Zhao, Y.5
Chen, Z.6
Herter-Sprie, G.S.7
Akbay, E.A.8
Tchaicha, J.H.9
Altabef, A.10
-
31
-
-
84935004492
-
EGFR-TKI downregulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-B
-
Lin K, Cheng J, Yang T, Li Y and Zhu B: EGFR-TKI downregulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-B. Biochem Biophys Res Commun 463: 95-101, 2015.
-
(2015)
Biochem Biophys Res Commun
, vol.463
, pp. 95-101
-
-
Lin, K.1
Cheng, J.2
Yang, T.3
Li, Y.4
Zhu, B.5
-
32
-
-
77957664158
-
Programmed death-1 upregulation is correlated with dysfunction of tumorinfiltrating CD8+ T lymphocytes in human non-small cell lung cancer
-
Zhang Y, Huang S, Gong D, Qin Y and Shen Q: Programmed death-1 upregulation is correlated with dysfunction of tumorinfiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 7: 389-395, 2010.
-
(2010)
Cell Mol Immunol
, vol.7
, pp. 389-395
-
-
Zhang, Y.1
Huang, S.2
Gong, D.3
Qin, Y.4
Shen, Q.5
-
33
-
-
84873666114
-
Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study
-
Chen YB, Mu CY and Huang JA: Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study. Tumori 98: 751-755, 2012.
-
(2012)
Tumori
, vol.98
, pp. 751-755
-
-
Chen, Y.B.1
Mu, C.Y.2
Huang, J.A.3
-
34
-
-
80052476869
-
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
-
Mu CY, Huang JA, Chen Y, Chen C and Zhang XG: High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 28: 682-688, 2011.
-
(2011)
Med Oncol
, vol.28
, pp. 682-688
-
-
Mu, C.Y.1
Huang, J.A.2
Chen, Y.3
Chen, C.4
Zhang, X.G.5
-
35
-
-
84964792419
-
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2
-
Robert L, Ribas A and Hu-Lieskovan S: Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2 Semin Immunol 28: 73-80, 2016.
-
(2016)
Semin Immunol
, vol.28
, pp. 73-80
-
-
Robert, L.1
Ribas, A.2
Hu-Lieskovan, S.3
-
36
-
-
84915750492
-
Universes collide: Combining immunotherapy with targeted therapy for cancer
-
Wargo JA, Cooper ZA and Flaherty KT: Universes collide: Combining immunotherapy with targeted therapy for cancer. Cancer Discov 4: 1377-1386, 2014.
-
(2014)
Cancer Discov
, vol.4
, pp. 1377-1386
-
-
Wargo, J.A.1
Cooper, Z.A.2
Flaherty, K.T.3
|